Traders should monitor for future definitive agreements and supply terms, which could confirm commercial scale and revenue potential. The partnership provides ZEO with access to a large clinical network, potentially accelerating commercialization of its biologic therapeutics.
Price Chart
Executive Summary
Zeo ScientifiX announced a memorandum of understanding (MOU) with Regen Therapy to establish an exclusive strategic collaboration, positioning ZEO as the core supplier of advanced biologic therapeutics for Regen Therapy's clinical platform. The partnership aims to integrate ZEO's biologic innovations into a scalable, data-driven longevity and regenerative care ecosystem.
Key Facts
- Zeo ScientifiX entered into a non-binding MOU with Regen Therapy for an exclusive scientific and biologics collaboration.
- ZEO will serve as the core supplier of advanced biologic therapeutics for Regen Therapy's next-generation regenerative offerings.
- The collaboration supports development and supply of therapeutics based on ZEO's expertise in extracellular vesicle biology and perinatal-derived therapeutics.
- Regen Therapy has a network of over 3,000 clinics and 24,000 practitioners across the U.S.
- The partnership is part of a broader ecosystem that includes Stealth Health and Metabolic Code® for telemedicine and data-driven longevity programming.
Financial Impact
Undisclosed financial terms; potential future revenue from supply agreement and expanded market access.
Risk Factors
- The MOU is non-binding and does not guarantee a definitive agreement.
- No financial terms or revenue projections were disclosed, making near-term impact speculative.
- ZEO operates on the OTC market, which may limit liquidity and increase volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-003301 |
| Document: zeoscientifix_ex99-1.htm | 0001829126-26-003301 |
| Document: 0001829126-26-003301-index-headers.html | 0001829126-26-003301 |
| Document: 0001829126-26-003301-index.html | 0001829126-26-003301 |
| Document: 0001829126-26-003301.txt | 0001829126-26-003301 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+20 | — | — |
Sep 15, 2026 5w ago | 8-K | $1.36 $1.15 | ▼ −15.44% | ▼ −18.42% | $1.55 (+13.97%) |
Sep 1, 2026 7w ago | 8-K | $1.20 $1.39 | ▲ +15.83% | ▲ +14.65% | $1.55 (+29.17%) |
Aug 4, 2026 11w ago | 8-K | $1.40 $1.20 | ▼ −14.16% | ▼ −12.93% | $1.55 (+10.87%) |
Jul 21, 2026 13w ago | 8-K | $1.69 $1.55 | ▼ −8.28% | ▼ −10.85% | $1.55 (−8.28%) |
Jul 8, 2026 15w ago | 8-K | $1.80 $1.40 | ▼ −22.33% | ▼ −25.61% | $1.55 (−13.89%) |
Jul 1, 2026 16w ago | 8-K | $1.77 $1.65 | ▼ −6.78% | ▼ −4.59% | $1.55 (−12.43%) |
Jun 16, 2026 18w ago | 8-K | $1.72 $1.94 | ▲ +12.79% | ▲ +11.93% | $1.55 (−9.88%) |
Jun 9, 2026 19w ago | 8-K | $1.67 $1.80 | ▲ +7.78% | ▲ +6.39% | $1.55 (−7.19%) |
May 27, 2026 21w ago | 8-K | $1.85 $1.70 | ▼ −8.11% | ▼ −6.21% | $1.55 (−16.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers